Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC527-X fluorescence imaging during breast cancer surgery (phase II, single-arm)
ChiCTR2600129489Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NC527-X in breast cancer and ductal carcinoma in situ (DCIS) (5 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: Specificity (true negative rate), Sensitivity (true positive rate) and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
NC527-X
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on ChiCTR2600129489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129489.